Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant mesothelioma of any of the following subtypes:
• * Epithelial
• * Sarcomatoid
• * Mixed
• Any site of origin of malignant mesothelioma allowed including, but not limited to, any of the following:
• * Pleura
• * Peritoneum
• * Pericardium
• * Tunica vaginalis
• Pathology blocks or slides from a core surgical biopsy must be available
• Not amenable to curative surgery
• Measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques (CT scan , MRI, or x-ray) or as ≥ 10 mm with spiral CT scan
• * Patients with pleural rind only disease must have at least one level with one rind measurement ≥ 1.5 cm
• * Lesions that are considered nonmeasurable include the following:
• * Bone lesions
• * Leptomeningeal disease
• * Ascites
• * Pleural/pericardial effusion
• * Lymphangitis cutis/pulmonis
• * Abdominal masses that are not confirmed and followed by imaging techniques
• * Cystic lesions
• Prior treatment with one and only one systemic chemotherapy regimen, which must have included pemetrexed disodium required
• * Treatment may have been with pemetrexed disodium alone or in combination with any other agent
• No symptomatic pleural effusions, unless the patient undergoes a therapeutic thoracentesis
• * Patients with pleural effusions who have had a pleurodesis are eligible
• No known brain metastases
• May be registered on CALGB-150707 companion study
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Granulocytes ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Total bilirubin ≤ 2 x upper limit of normal (ULN)
• AST (SGOT) ≤ 2.5 x ULN
• Creatinine clearance ≥ 60 mL/min
• INR \< 1.5
• PTT \< 40 seconds
• QTc \< 450 msec
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No significant cardiac disease, including any of the following:
• * New York Heart Association (NYHA) class III-IV congestive heart failure (CHF)
• * Unstable angina
• * Myocardial infarction or ventricular tachyarrhythmia within 6 months of study entry
• * Ejection fraction less than institutional normal (in patients with a history of CHF or currently with NYHA class I or II CHF)
• * Prolonged QTc \> 450 msec (Fridericia correction)
• * Major conduction abnormality, unless a cardiac pacemaker is present
• * Hypokalemia or hypomagnesemia that cannot be corrected
• No history of significant bleeding disorder unrelated to cancer, including any of the following:
• * Congenital bleeding disorder (e.g., von Willebrand disease)
• * Acquired bleeding disorder within the past year (e.g., acquired anti-factor VIII antibodies)
• * Ongoing or recent (≤ 3 months) significant GI bleeding or hemoptysis
• No requirement for supplemental oxygen (i.e., pulse oximetry \< 89% at rest)
• PRIOR CONCURRENT THERAPY:
• At least 4 weeks since prior pemetrexed disodium-containing chemotherapy
• At least 4 weeks since prior major surgery
• At least 4 weeks since prior radiation therapy
• * Measurable disease must be outside the radiation port
• Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) allowed
• * Intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy
• At least 7 days since prior and no concurrent antithrombotic or anti-platelet agents, including any of the following:
• * Aspirin or aspirin-containing combinations
• * Clopidogrel
• * Dipyridamole
• * Tirofiban
• * Epoprostenol
• * Eptifibatide
• * Cilostazol
• * Abciximab
• * Ticlopidine
• * Warfarin
• * Low-dose warfarin for prophylaxis to prevent catheter thrombosis allowed
• * Heparin or low molecular weight heparin
• * Heparin for IV line flush allowed
• At least 7 days since prior and no concurrent use of the following drugs:
• * Itraconazole
• * Ketoconazole (at doses \> 200 mg/day)
• * Miconazole
• * Voriconazole
• * Telithromycin
• * Primidone
• * Rifabutin
• * Rifampin
• * St. John's wort
• * Carbamazepine
• * Oxcarbazepine
• * Rifapentine
• * Phenobarbital
• * Phenytoin
• * Quinidine
• * Procainamide
• * Disopyramide
• * Amiodarone
• * Sotalol
• * Ibutilide
• * Dofetilide
• * Erythromycin
• * Clarithromycin
• * Chlorpromazine
• * Haloperidol
• * Mesoridazine
• * Thioridazine
• * Pimozide
• * Bepridil
• * Droperidol
• * Halofantrine
• * Levomethadyl
• * Sparfloxacin
• No concurrent H2 blockers or proton pump inhibitors
• No bisphosphonate therapy during the first 8 weeks of study treatment
• No concurrent hormones or other chemotherapeutic agents except for steroids administered for dasatinib-related pleural effusion or hormones administered for non-disease-related conditions (e.g., insulin for diabetes)
• No concurrent palliative radiation therapy